MS Treatment Advances: New Therapies Offer Hope
Multiple Sclerosis (MS) treatment has seen significant advancements with numerous experimental therapies and approved disease-modifying therapies (DMTs) showing promise. The FDA has approved over a dozen DMTs for various types of MS, offering hope to patients and their families.
One such therapy, siponimod (Mayzent), has proven effective in reducing relapse rates in people with active secondary progressive MS (SPMS), as well as treating relapsing-remitting MS (RRMS) and clinically isolated syndrome (CIS). Similarly, cladribine (Mavenclad) treats RRMS and active SPMS. Ocrelizumab (Ocrevus), the first approved DMT for primary progressive MS (PPMS), treats all four types of MS.
TG Therapeutics is currently conducting a Phase 3 trial for subcutaneous BRIUMVI, which could potentially offer both intravenous and subcutaneous options if approved by 2028. However, there is no recent public information on a company receiving approval for a new DMT for MS. Notably, daclizumab (Zinbryta) was withdrawn due to potential risks of inflammatory brain disorders. Ponesimod (Ponvory) and ublituximab (Briumvi) have also been approved to treat various types of MS, with fingolimod (Gilenya) being the first DMT approved for pediatric MS.
Experimental therapies like ibudilast, clemastine fumarate, and hematopoietic stem cell transplantation are also showing promise in treating MS. With continued research and development, the future of MS treatment looks increasingly hopeful, offering patients a range of options to manage their condition.
